Advertisement
Advertisement
XFOR
X4 Pharmaceuticals, Inc. Common Stock
4.23
USDSponsored
-0.11
-2.53%
May 13, 16:00 UTC -4
Closed
Pre-Market
4.24
0.00
+0.12%
XFOR Earnings Reports
Positive Surprise Ratio
XFOR beat 19 of 33 last estimates.
58%
Next Report
Date of Next Report
Aug 06, 2026
Estimate for Q2 26 (Revenue/ EPS)
$2.18M
/-$0.19
Implied change from Q1 26 (Revenue/ EPS)
-19.65%
/+18.75%
Implied change from Q2 25 (Revenue/ EPS)
+10.29%
/-94.52%
X4 Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On May 06, 2026, XFOR reported earnings of -0.16 USD per share (EPS) for Q1 26, beating the estimate of -0.20 USD, resulting in a 21.57% surprise. Revenue reached 2.71 million, compared to an expected 3.26 million, with a -17.03% difference. The market reacted with a +4.29% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 5 analysts forecast an EPS of -0.19 USD, with revenue projected to reach 2.18 million USD, implying an increase of 18.75% EPS, and decrease of -19.65% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were X4 Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, X4 Pharmaceuticals, Inc. Common Stock reported EPS of -$0.16, beating estimates by 21.57%, and revenue of $2.71M, -17.03% below expectations.
How did the market react to X4 Pharmaceuticals, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 4.29%, changed from $4.20 before the earnings release to $4.38 the day after.
When is X4 Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 06, 2026.
What are the forecasts for X4 Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 5
analysts, X4 Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.19 and revenue of $2.18M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement